8-K: Neuronetics Secures $90 Million Credit Facility with Perceptive Advisors

Neuronetics, Inc. has entered into a new debt agreement with Perceptive Advisors, securing up to $90 million to refinance existing debt and support growth initiatives.

Summary

• Neuronetics, Inc. has secured a credit facility of up to $90 million from Perceptive Advisors.
• The agreement includes an initial tranche of $50 million, which was received at closing.
• A second tranche of $15 million is available upon achieving certain milestones until December 31, 2025.
• A third tranche of $25 million can be requested by the company on or before June 30, 2026.
• The initial $50 million tranche will be used to pay off the company's existing $60 million SLR Capital term loan.
• The loan has a 5-year term, maturing on the fifth anniversary of the closing date.
• Interest will accrue at a rate equal to the greater of (a) forward-looking one-month term SOFR and (b) 4.50% per annum, plus an applicable margin of 7.00%.

Sentiment

Score: 7

Explanation: The document is generally positive, highlighting the new funding and its potential to support growth. However, the debt and warrant issuance introduce some risk, preventing a higher score.

Positives

• The new credit facility strengthens Neuronetics' balance sheet and provides additional financial flexibility.
• The funding will support the company's commercial initiatives, expansion of clinical indications, and adoption of NeuroStar therapy.
• The partnership with Perceptive Advisors reflects confidence in Neuronetics' growth potential and the increasing adoption of NeuroStar therapy.

Negatives

• The company has taken on a significant amount of debt.
• The company has issued warrants which may dilute existing shareholders.

Risks

• The company's ability to access the second and third tranches of the loan is contingent on achieving certain milestones and lender approval.
• The company is subject to financial covenants under the credit agreement.
• The company is subject to a floating interest rate which may increase over time.

Future Outlook

The company plans to use the funding to invest in commercial initiatives, expand clinical indications, and drive adoption of NeuroStar therapy.

Management Comments

• Keith Sullivan, President and Chief Executive Officer of Neuronetics, stated that the new credit facility strengthens the company's balance sheet and provides additional financial flexibility.
• Sam Chawla at Perceptive Advisors expressed excitement to partner with Neuronetics and support their mission to improve the lives of patients suffering from depression and other mental health conditions.

Industry Context

This announcement reflects a trend of increased investment in medical technology companies focused on mental health, as well as the growing adoption of non-invasive neuromodulation therapies.

Comparison to Industry Standards

• The interest rate of SOFR plus 7.00% is within the typical range for venture debt facilities for companies of this size and stage.
• The use of warrants is a common practice in venture debt financings, providing lenders with potential upside in the company's equity.
• The 5-year term is a standard duration for term loans in the medical device industry.
• The tiered structure of the loan, with tranches available upon achieving milestones, is a common approach to manage risk and incentivize performance.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of warrants.
• Employees may benefit from the company's increased financial stability and growth potential.
• Customers may benefit from the company's continued investment in its products and services.
• Creditors may benefit from the company's improved financial position.

Next Steps

• Neuronetics will use the initial $50 million tranche to pay off its existing SLR Capital term loan.
• The company will work towards achieving the milestones required to access the second tranche of $15 million.
• Neuronetics may request the third tranche of $25 million on or before June 30, 2026.

Key Dates

Keywords

credit facility, debt financing, term loan, Perceptive Advisors, Neuronetics, NeuroStar, mental health, neuromodulation, warrants, refinance